Total Payments
$32,904
2024 Payments
$1,126
Companies
27
Transactions
203
Medicare Patients
1,190
Medicare Billing
$150,464
Payment Breakdown by Category
Research$27,333 (83.1%)
Food & Beverage$4,304 (13.1%)
Travel$1,192 (3.6%)
Other$75.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27,333 | 6 | 83.1% |
| Food and Beverage | $4,304 | 193 | 13.1% |
| Travel and Lodging | $1,192 | 3 | 3.6% |
| Grant | $75.00 | 1 | 0.2% |
Payments by Type
Research
$27,333
4 transactions
General
$5,571
197 transactions
Ownership
$0
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $27,333 | 4 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,179 | 60 | $0 (2024) |
| Boston Scientific Corporation | $884.71 | 6 | $0 (2024) |
| Cook Medical LLC | $870.24 | 4 | $0 (2018) |
| ABBVIE INC. | $684.83 | 40 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $321.23 | 14 | $0 (2024) |
| Celgene Corporation | $276.95 | 11 | $0 (2023) |
| Intercept Pharmaceuticals, Inc. | $197.43 | 9 | $0 (2024) |
| Janssen Biotech, Inc. | $158.43 | 8 | $0 (2024) |
| GENZYME CORPORATION | $150.31 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,126 | 48 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($306.27) |
| 2023 | $2,315 | 64 | Eli Lilly and Company ($1,075) |
| 2022 | $26,822 | 30 | Eli Lilly and Company ($26,258) |
| 2021 | $268.92 | 14 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($116.96) |
| 2020 | $269.35 | 17 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($83.06) |
| 2019 | $486.44 | 22 | Endogastric Solutions, Inc ($90.04) |
| 2018 | $1,577 | 7 | Cook Medical LLC ($870.24) |
| 2017 | $39.85 | 1 | AbbVie, Inc. ($39.85) |
All Payment Transactions
203 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: Gastroenterology | ||||||
| 12/13/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $34.74 | General |
| Category: LIVER DISEASE | ||||||
| 12/02/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: Gastroenterology | ||||||
| 11/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $33.16 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Gastroenterology | ||||||
| 10/14/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Immunology | ||||||
| 10/08/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $10.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/30/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $28.11 | General |
| Category: THERAPY FOR CSID | ||||||
| 09/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: Gastroenterology | ||||||
| 09/11/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $22.01 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: Gastroenterology | ||||||
| 08/22/2024 | Boston Scientific Corporation | Resolution 360 Clip (Device) | Food and Beverage | In-kind items and services | $49.37 | General |
| Category: Resolution 360 Clip_ENDO | ||||||
| 08/20/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: IMMUNOLOGY | ||||||
| 08/19/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $33.15 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.39 | General |
| Category: Immunology | ||||||
| 08/14/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Gastroenterology | ||||||
| 07/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Gastroenterology | ||||||
| 06/21/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/13/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | Cash or cash equivalent | $116.53 | General |
| Category: Immunology | ||||||
| 06/12/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: Gastroenterology | ||||||
| 06/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.37 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $26,258 | 2 |
| A PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $641.29 | 1 |
| A PHASE 3 MULTICENTER OPEN LABEL LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | Eli Lilly and Company | $433.85 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 313 | 341 | $252,192 | $37,576 |
| 2022 | 11 | 278 | 337 | $198,394 | $36,028 |
| 2021 | 13 | 306 | 382 | $186,045 | $42,082 |
| 2020 | 12 | 293 | 363 | $151,610 | $34,778 |
Total Patients
1,190
Total Services
1,423
Medicare Billing
$150,464
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 50 | 50 | $72,435 | $9,930 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 42 | 50 | $12,650 | $4,808 | 38.0% |
| 43242 | Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 17 | 17 | $21,038 | $3,246 | 15.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 61 | 63 | $51,629 | $3,190 | 6.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 29 | $8,932 | $3,110 | 34.8% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 26 | 30 | $29,700 | $3,049 | 10.3% |
| 43259 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 15 | 16 | $15,840 | $2,820 | 17.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 29 | $5,423 | $1,995 | 36.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 14 | 14 | $14,553 | $1,810 | 12.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 21 | $3,234 | $1,390 | 43.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,812 | $1,311 | 34.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $12,947 | $917.62 | 7.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 34 | 35 | $50,178 | $6,593 | 13.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 45 | $11,247 | $4,792 | 42.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 40 | 41 | $12,488 | $4,645 | 37.2% |
| 43242 | Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 22 | 23 | $27,788 | $4,536 | 16.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 31 | 70 | $10,360 | $4,147 | 40.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 47 | 48 | $38,964 | $2,831 | 7.3% |
| 43259 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 14 | 14 | $13,770 | $2,491 | 18.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 20 | 20 | $4,905 | $1,735 | 35.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $4,473 | $1,721 | 38.5% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2022 | 12 | 15 | $14,850 | $1,441 | 9.7% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 13 | 13 | $9,372 | $1,096 | 11.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 61 | $12,200 | $6,878 | 56.4% |
| 43242 | Ultrasound guided needle aspiration or biopsy of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 32 | 33 | $37,125 | $6,458 | 17.4% |
About Dr. Liam Zakko, M.D
Dr. Liam Zakko, M.D is a Gastroenterology healthcare provider based in Lebanon, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2011. The National Provider Identifier (NPI) number assigned to this provider is 1932499092.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Liam Zakko, M.D has received a total of $32,904 in payments from pharmaceutical and medical device companies, with $1,126 received in 2024. These payments were reported across 203 transactions from 27 companies. The most common payment nature is "" ($27,333).
As a Medicare-enrolled provider, Zakko has provided services to 1,190 Medicare beneficiaries, totaling 1,423 services with total Medicare billing of $150,464. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Lebanon, NH
- Active Since 04/11/2011
- Last Updated 07/10/2018
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1932499092
Products in Payments
- XIFAXAN (Drug) $1,105
- GENERAL THERAPIES (Device) $706.46
- ZEPOSIA (Drug) $222.95
- ENTYVIO (Biological) $215.57
- OCALIVA (Drug) $197.43
- RINVOQ (Biological) $177.11
- SKYRIZI (Biological) $164.25
- STELARA (Biological) $158.43
- DUPIXENT (Biological) $150.31
- LINZESS (Drug) $128.48
- CREON (Drug) $124.57
- OMVOH (Drug) $116.53
- ESOPHYX (Device) $90.04
- VIBERZI (Drug) $81.06
- TRULANCE (Drug) $74.03
- REBYOTA (Biological) $71.26
- EXALT Model D (Device) $66.98
- DIFICID (Drug) $65.87
- GATTEX (Drug) $62.22
- GENERAL THERAPIES (Device) $61.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Lebanon
Corey Siegel, M.d, M.D
Gastroenterology — Payments: $666,177
Gastroenterology $666,177
Brian Lacy, Ph.d; M.d, PH.D; M.D
Gastroenterology — Payments: $272,238
Gastroenterology $272,238
Audrey Calderwood, Md, MD
Gastroenterology — Payments: $93,062
Gastroenterology $93,062
Dr. Shelby Sullivan, Md, MD
Gastroenterology — Payments: $66,641
Gastroenterology $66,641
Stuart Gordon, M.d, M.D
Gastroenterology — Payments: $66,131
Gastroenterology $66,131
Dr. Michael Winter, Md, MD
Gastroenterology — Payments: $54,448
Gastroenterology $54,448